International Journal of Psychiatry in Clinical Practice
June 1, 2024
Ludovic Samalin, Lila Mekaoui, Pierre De Maricourt et al.
3 citations
ESKALE is a French, multicentre, observational study of adults with treatment-resistant depression (TRD) treated with esketamine. This interim analysis describes baseline demographic and clinical characteristic evolution in patients included and treated from early access program to post-marketing launch. Data were collected from medical records and included patient characteristics, disease...
Psychedelic Medicine
June 1, 2024
Ryan Yermus, John Bottos, Nathan Bryson et al.
13 citations
Ketamine-assisted psychotherapy (KAP) is an emerging treatment option to alleviate treatment-resistant affective disorders, but its long-term effectiveness remains unclear. To examine the treatment effects of KAP on anxiety, depression, and post-traumatic stress disorder (PTSD) at 1, 3, and 6 months post-treatment. This retrospective effectiveness study included self-reported outcomes from...
Molecules
May 23, 2024
Shiyun Li, Bin Wen, Wei Zhao et al.
4 citations
Depression is a chronic, severe, and often life-threatening neurological disorder. It not only causes depression in patients and affects daily life but, in severe cases, may lead to suicidal behavior and have adverse effects on families and society. In recent years, it has been found that sub-anesthetic doses of ketamine have a rapid antidepressant effect on patients with treatment-resistant...
Neuroscience Letters
May 14, 2024
Daniele Cavaleri, Ilaria Riboldi, Cristina Crocamo et al.
13 citations
The antidepressant effects of ketamine and esketamine are well-documented. Nonetheless, most of the underlying molecular mechanisms have to be uncovered yet. In the last decade, metabolomics has emerged as a useful means to investigate the metabolic phenotype associated with depression as well as changes induced by antidepressant treatments. This mini-review aims at summarizing the main...
Jurnal Psikiatri Surabaya
May 13, 2024
Satrio Wahyu Nugroho, Agustina Konginan, Gadis Meinar Sari et al.
1 citation
Introductions: In Indonesia, a median of 6.1% of people diagnosed with depression disorder are people over 15 years old. Only 9% of that amount underwent medical treatment, while the rest, 91%, did not undergo treatment for their depressive conditions. Inadequate and inappropriate treatment of depression will lead to Treatment-Resistant Depression (TRD). Using ketamine as a pharmacotherapy...
Frontiers in Psychiatry
May 10, 2024
Qin Xiang Ng, Yu Liang Lim, Clarence Ong et al.
3 citations
Objective: To investigate societal perceptions of ketamine's use in depression therapy by analysing Twitter posts from January 1, 2010 to April 1, 2023. Methods: Using Twitter as the social media platform of choice, and employing search terms based on (depression OR depressed OR depressive) AND (ketamine OR esketamine OR Spravato), we collected English-language tweets from January 1, 2010, to...
BJPsych Open
May 10, 2024
Luke A. Jelen, Rupert McShane, Allan H. Young
7 citations
In this editorial, we emphasise the efficacy and challenges of using ketamine in treatment-resistant depression. We highlight the need for comprehensive evidence-based guidelines to manage the use of both licensed and off-licence ketamine formulations and discuss recent efforts by Beaglehole et al to develop ketamine guidelines in New Zealand. We finally advocate for national registries to...
BMC Psychiatry
May 7, 2024
Ahmad Zolghadriha, Afagh Anjomshoaa, Mohammad Reza Jamshidi et al.
24 citations
Retracted
Major depressive disorder (MDD) is the most disabling and burdensome mental disorder, negatively affecting an individual's quality of life and daily functioning. the current study was conducted with the aim of investigating the clinical effects of intravenous ketamine on symptoms of MDD and suicidal ideation. The current randomized clinical trial was carried out on 64 patients diagnosed with...
Research Posters
May 2, 2024
Jaylyn Thompson, David F Lo, Alexis Foschini et al.
The purpose of this review is to explore perinatal ketamine’s potential for reducing postpartum depression after cesarean section. Articles reviewed from Pubmed, Cochrane, and Web of Science using specific search terms. 8 final papers were used for review after excluding duplicates and irrelevant titles and abstracts. Ketamine showed potential in reducing postpartum depression symptoms post...
Journal of the American Academy of Child & Adolescent Psychiatry
May 2024
Yanling Zhou, Xiaofeng Lan, Chengyu Wang et al.
Suicide is a major cause of death in adolescents with limited treatment options. Ketamine and its enantiomers have shown rapid anti-suicidal effects in adults with major depressive disorder (MDD), but their efficacy in adolescents is unknown. We conducted an active, placebo-controlled trial to determine the safety and efficacy of intravenous esketamine in this population. A total of 54...